Rebif recombinant interferon beta-1a data

At the American Neurological Association meeting in San Diego, Ares-Serono presented positive results from its double-blind Phase III trial of Rebif in 560 patients with relapsing-remitting MS. Patients with

Read the full 291 word article

How to gain access

Continue reading with a
two-week free trial.